Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has provided an announcement.
Clarity Pharmaceuticals has announced the treatment of the first participant in the Phase II Cohort Expansion of the SECuRE trial, using an enhanced formulation of 67Cu-SAR-bisPSMA. This phase follows the successful completion of the Dose Escalation Phase and aims to evaluate the safety and efficacy of this treatment in metastatic castration-resistant prostate cancer, particularly in the pre-chemotherapy setting. The trial includes a protocol amendment to test a combination therapy with enzalutamide, reflecting promising results from previous studies and expert consultations. The improved formulation offers room temperature stability, essential for large-scale manufacturing and commercialization, potentially reducing supply issues and shipment delays.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes. The company specializes in Targeted Copper Theranostic (TCT) products, utilizing proprietary sarcophagine (SAR) technology to securely hold copper isotopes for both imaging and therapy, with a particular focus on prostate cancer.
YTD Price Performance: -61.27%
Average Trading Volume: 2,101,033
Technical Sentiment Signal: Buy
Current Market Cap: A$519M
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.